Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by Steve888on Sep 30, 2017 12:28pm
57 Views
Post# 26762516

RE:RE:Concerns to consider

RE:RE:Concerns to considerJuan, the purpose for us to play ICO is making money. (1)if IMNP is delisted and even ICO survives, the ICO share price could drop significantly. So, we lose money. (2) Refinance is always hard for any penny stocks, especially when share price is below 5 cents. Without money, the share price will drop.anf we lose money. (3) if the trial results are bad, the share price will be down to 0.005 if not zero although ICO may still have life. But we lose money. (4) tax season bring share dumping. If it happens, share price drops and we lose money.
juansito wrote: Steve I think your concerns are legitimes but :
1) Is not first time IMNP received these kind of letters and alwais survive...so probably these time is the same...imo IMNP will continue or be bougth...any way Ico will survive IMNP delisting if occurs...
2)Ico cash is good until H2 2018 and Ico has way to finance w out dilution...(gates fundation grants, or canada grants) as already done.
3) these is all what junior pharma is...take or leave it
4) look other years...tax season didnt make any differences for ICO
and last...if anything will be so clear cut so nobody loose or win...
just a risk reward ecuation...
GLTA
holding not selling less than 7 to 10



<< Previous
Bullboard Posts
Next >>